Prime Medicine reports ~$101.8M cash as of June 30; terminates ATM prospectus

Prime Medicine, Inc.

Preliminary cash, equivalents, and short-term investments ~$101.8M at June 30, 2025; plus $13.7M restricted cash.
Terminated ATM prospectus under S-3 effective July 30; no further sales pending new filing.
Sales agreement with Jefferies remains in force but ATM program currently inactive.
Updated July 2025 corporate presentation posted on company website; includes pipeline updates.
Company expects to report complete Q2 results in Form 10-Q; estimates subject to final adjustments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.